# US 2004/0018149 A1 · Three-dimensional skin model

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0018149 A1
- Document ID: US20040018149A1
- Status: Published application
- Kind: A1
- Application number: 10/296,967
- Filed: 2003-07-17
- Published: 2004-01-29
- Earliest claimed: 2000-05-31
- Assignees: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- Inventors: Michael Noll; Thomas Grave
- Web page: https://patentgrep.com/patent/US20040018149A1

## CPC

- A61L 27/3813: {Epithelial cells, e.g. keratinocytes, urothelial cells}
- A61L 27/24: Collagen
- A61L 27/3804: {characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells}
- A61L 27/3817: {Cartilage-forming cells, e.g. pre-chondrocytes}
- A61L 27/3852: {Cartilage, e.g. meniscus}
- A61L 27/3895: {using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions}
- A61L 27/60: Materials for use in artificial skin
- C12N 5/0062: {General methods for three-dimensional culture}
- C12N 5/0655: {Chondrocytes; Cartilage}
- C12N 5/0698: {Skin equivalents}
- G01N 33/5082: {Supracellular entities, e.g. tissue, organisms}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- A61L 2430/40: Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
- C12N 2502/094: keratinocytes
- C12N 2502/1323: Adult fibroblasts
- C12N 2503/06: Screening or testing on artificial skin
- C12N 2533/52: Fibronectin; Laminin
- C12N 2533/54: Collagen; Gelatin
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods for cultivating dermal fibroblasts, methods for preparing in vitro dermis equivalents, methods for preparing three-dimensional in vitro skin equivalents, an in vitro dermis equivalent, a three-dimensional in vitro skin equivalent, and methods for determining the effect of a chemical substance or of an agent on human skin cells using the in vitro dermis equivalent and/or the in vitro skin equivalent.

## Claims

### Claim 1

Method for multiplying dermal fibroblasts, wherein the dermal fibroblasts are cultivated embedded in a three-dimensional, gel-like biomatrix, containing at least 3 mg/ml of collagen in buffered, serum-containing cell culture medium, whereby the collagen solution used for the production of the biomatrix has a high content of non-denatured, native collagen.

### Claim 2

Method for studying the function, morphology and/or differentiation status of dermal fibroblasts, wherein the dermal fibroblasts to be studied are introduced into a three-dimensional, gel-like biomatrix containing at least 3 mg/ml of collagen in buffered, serum-containing cell culture medium, whereby the collagen solution used for the production of the biomatrix has a high content of non-denatured, native collagen, are cultivated therein, and are tested simultaneously and/or subsequently.

### Claim 3

Method for producing an in vitro dermis equivalent, wherein dermal fibroblasts are embedded into a three-dimensional, gel-like biomatrix containing at least 3 mg/ml of collagen in buffered, serum-containing cell culture medium, whereby the collagen solution used for the production of the biomatrix has a high content of non-denatured, native collagen, and are cultivated therein in such a way that an in vitro dermis equivalent is obtained.

### Claim 4 (depends on 3)

Method according to claim 3, wherein the cultivation of the dermal fibroblasts comprises an at least one- to two-day submerse culture.

### Claim 5 (depends on 3, 4)

Method for producing an in vitro dermis equivalent according to claim 3 or 4, comprising the extraction of collagen-containing tissue, the transfer of the collagen-containing tissue in acidic solution, the incubation of the collagen tissue transferred into the acidic solution at 2 to 10° C., particularly at 4° C., the centrifuging-off of undissolved collagen parts, the mixing of the obtained collagen solution at 2 to 10° C., preferably at 4° C., with a solution containing the dermal fibroblasts, cell culture medium, serum, and buffer, and the gelling of the mixed solution by increasing the temperature.

### Claim 6 (depends on 3, 4, 5)

Method according to one of claims 3 to 5, wherein the dermal fibroblasts, after cultivation in the three-dimensional, gel-like biomatrix, are removed from the latter and are further cultivated in a higher cell density so that an in vitro dermis equivalent is obtained.

### Claim 7

Method for producing a three-dimensional in vitro skin equivalent, wherein dermal fibroblasts are embedded into a three-dimensional, gel-like biomatrix containing at least 3 mg/ml of collagen in buffered, serum-containing cell culture medium, whereby the collagen solution used for the production of the biomatrix has a high content of non-denatured, native collagen, and are subjected to an at least one-to two-day submerse culture therein, and wherein keratinocytes are then seeded in a cell culture medium on the biomatrix and are then further cultivated so that a three-dimensional in vitro skin equivalent is obtained.

### Claim 8 (depends on 7)

Method according to claim 7, wherein the cultivation of the keratinocytes comprises at least a five to six day submerse culture and at least a 12- to 14-day airlift culture.

### Claim 9 (depends on 7, 8)

Method according to claim 7 or 8, wherein the keratinocytes have a high content of undifferentiated basal stem cells.

### Claim 10 (depends on 7, 8, 9)

Methods according to one of claims 7 to 9, wherein before, during, or after the seeding of the keratinocytes, other skin cell types, such as melanocytes, immune cells and/or endothelial cells are seeded and cultivated on the biomatrix.

### Claim 11 (depends on 7, 8, 9, 10)

Method for producing a three-dimensional in vitro skin equivalent according to one of claims 7 to 10, comprising the extraction of collagen-containing tissue, the transfer of the collagen-containing tissue in acidic solution, the incubation of the collagen tissue transferred into the acidic solution at 2 to 10° C., particularly at 4° C., the centrifuging-off of undissolved collagen parts, the mixing of the obtained collagen solution at 2 to 10° C., preferably at 4° C., with a solution containing the dermal fibroblasts, cell culture medium, serum, and buffer, and the gelling of the mixed solution by increasing the temperature, the incubation of the gelled mixture at 37° C., and the seeding of the keratinocytes and/or of the other skin cell types onto the incubated, gelled mixture.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

Method according to one of claims 1 to 11, wherein the biomatrix containing embedded, dermal fibroblasts is prepared by stirring collagen fibers extracted from a tissue in acidic solution for 3 to 14 days at 2 to 10° C., preferably at 4° C., undissolved collagen parts are centrifuged off, and the obtained, finished collagen solution with a collagen content of 3 mg/ml to 8 mg/ml is mixed with a solution containing dermal fibroblasts, cell culture medium, serum, and buffer at 2 to 10° C., preferably at 4° C., and is then gelled at a higher temperature, preferably at room temperature up to 37° C.

### Claim 13 (depends on 12)

Method according to claim 12, wherein the acidic solution is acetic solution, in particular a 0.1% acetic acid solution.

### Claim 14 (depends on 12, 13)

Method according to claim 12 or 13, wherein the solution containing cell culture medium, serum, and buffer is mixed in a ratio of 1:2 with the collagen-containing solution.

### Claim 15 (depends on 3, 4, 5, 6, 12, 13, 14)

In vitro dermis equivalent, prepared in accordance with a method according to one of claims 3 to 6 or 12 to 14.

### Claim 16 (depends on 15)

Human in vitro dermis equivalent according to claim 15, prepared with human, dermal fibroblasts.

### Claim 17 (depends on 7, 8, 9, 10, 11, 12, 13, 14)

Three-dimensional in vitro skin equivalent, prepared in accordance with a method according to one of claims 7 to 14.

### Claim 18 (depends on 17)

Human, three-dimensional in vitro skin equivalent according to claim 17, prepared with human, dermal fibroblasts and human keratinocytes and potentially other human skin cell types.

### Claim 19 (depends on 15, 16)

Method for determining the effect of a chemical substance or of an agent on dermis cells, comprising the bringing into contact of the chemical substance or of the agent with an in vitro dermis equivalent according to claim 15 or 16, and for determining the interaction between dermis equivalent and the chemical substance or the agent.

### Claim 20 (depends on 17, 18)

Method for determining the effect of a chemical substance or of an agent on skin cells, comprising the bringing into contact of the chemical substance or of the agent with a three-dimensional in vitro skin equivalent according to claim 17 or 18, and for determining the interaction between skin equivalent and the chemical substance or the agent.
